Atrys Health, S.A. (ATRY.MC)
EUR 3.11
(0.32%)
EUR 3.11
(0.32%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -45.59 Million EUR | -94.26% |
| 2022 | -23.46 Million EUR | -1.17% |
| 2021 | -23.19 Million EUR | -1051.14% |
| 2020 | -2.01 Million EUR | -1823.11% |
| 2019 | -104.78 Thousand EUR | -974.3% |
| 2018 | 11.98 Thousand EUR | -87.66% |
| 2017 | 97.15 Thousand EUR | 54.13% |
| 2016 | 63.03 Thousand EUR | -95.13% |
| 2015 | 1.29 Million EUR | 304.37% |
| 2014 | 320.19 Thousand EUR | -4.85% |
| 2013 | 336.53 Thousand EUR | -50.64% |
| 2012 | 681.81 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -8.35 Million EUR | 63.01% |
| 2024 Q2 | -8.23 Million EUR | 1.36% |
| 2023 Q1 | -6.53 Million EUR | 67.5% |
| 2023 Q4 | -22.58 Million EUR | -159.79% |
| 2023 FY | -45.59 Million EUR | -94.26% |
| 2023 Q3 | -8.69 Million EUR | 62.21% |
| 2023 Q2 | -23 Million EUR | -252.28% |
| 2022 Q2 | -3.16 Million EUR | -128.76% |
| 2022 FY | -23.46 Million EUR | -1.17% |
| 2022 Q3 | -10.03 Million EUR | -216.93% |
| 2022 Q1 | -1.38 Million EUR | 93.06% |
| 2022 Q4 | -20.09 Million EUR | -100.25% |
| 2021 Q4 | -19.93 Million EUR | -104.46% |
| 2021 Q2 | -3.31 Million EUR | -78.44% |
| 2021 Q3 | -9.74 Million EUR | -194.27% |
| 2021 FY | -23.19 Million EUR | -1051.14% |
| 2021 Q1 | -1.85 Million EUR | 16.78% |
| 2020 FY | -2.01 Million EUR | -1823.11% |
| 2020 Q2 | -543.25 Thousand EUR | 0.0% |
| 2020 Q1 | -543.25 Thousand EUR | -132.46% |
| 2020 Q3 | -2.23 Million EUR | -310.63% |
| 2020 Q4 | -2.23 Million EUR | 0.0% |
| 2019 Q4 | -233.69 Thousand EUR | -100.0% |
| 2019 Q2 | 128.91 Thousand EUR | 100.0% |
| 2019 Q3 | -116.84 Thousand EUR | -190.64% |
| 2019 Q1 | 64.45 Thousand EUR | 128.44% |
| 2019 FY | -104.78 Thousand EUR | -974.3% |
| 2018 Q1 | 119.29 Thousand EUR | 141.48% |
| 2018 FY | 11.98 Thousand EUR | -87.66% |
| 2018 Q4 | -226.6 Thousand EUR | -100.0% |
| 2018 Q3 | -113.3 Thousand EUR | -147.49% |
| 2018 Q2 | 238.59 Thousand EUR | 100.0% |
| 2017 Q4 | 49.4 Thousand EUR | 0.0% |
| 2017 FY | 97.15 Thousand EUR | 54.13% |
| 2017 Q2 | 96.06 Thousand EUR | -0.0% |
| 2017 Q1 | 96.06 Thousand EUR | 157.32% |
| 2017 Q3 | 49.4 Thousand EUR | -48.57% |
| 2016 Q1 | 199.11 Thousand EUR | 0.0% |
| 2016 Q2 | 199.11 Thousand EUR | -0.0% |
| 2016 FY | 63.03 Thousand EUR | -95.13% |
| 2016 Q4 | -167.59 Thousand EUR | 0.0% |
| 2016 Q3 | -167.59 Thousand EUR | -184.17% |
| 2015 FY | 1.29 Million EUR | 304.37% |
| 2014 FY | 320.19 Thousand EUR | -4.85% |
| 2013 FY | 336.53 Thousand EUR | -50.64% |
| 2012 FY | 681.81 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Biotechnologies Assets SA | 1.57 Million EUR | 2996.864% |
| Pharma Mar, S.A. | 1.13 Million EUR | 4109.675% |
| Laboratorios Farmaceuticos Rovi, S.A. | 170.33 Million EUR | 126.765% |